In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...
9, California-based Terns Pharmaceuticals reported that its once-daily GLP-1 pill, TERN-601 ... oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients ...
Wegovy is part of a class of drugs called GLP-1 receptor agonists, and its active ingredient, semaglutide, is also approved to treat type 2 diabetes as Ozempic. Novo Nordisk’s trial was limited ...
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments ...